undamentalytics Newsletter
Sign in

Capricor Therapeutics, Inc. cash flow statement

In fiscal 2025, Capricor Therapeutics, Inc.'s operations generated −$69.8m of cash; it spent $2.9m on capital projects, leaving free cash flow of −$72.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations−5−2−61−11−14−14−14−7−10−175−26−40−70
Depreciation and amortisation000000000001112
Stock-based pay10002222123471017
Capital spending000000000112113
Free cash flow−5−2−61−11−15−14−14−7−11−183−27−41−73
Free cash flow after stock pay−5−3−60−13−17−16−16−8−13−21−2−34−51−90
Share buybacks———————000—————
Shares issued00—0161411792720526152237

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CAPR vs JANXCAPR vs CRSPABEO vs CAPR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Capricor Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Capricor Therapeutics, Inc.